Clinical Research Directory

Inclusion Criteria (for the 3 phases): * Subjects aged between 40 and 80 years * Both genders, of which at least 37% must be women to ensure representativeness * Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures * Written informed consent obtained prior to performing any protocol-related procedures. Inclusion criteria for Phase 2: Precision Screening: * High risk of developing Lung Cancer volunteers will be selected by Lung Cancer risk factors modelling. Inclusion criteria for Phase 3: Diagnosis: \- Patients diagnosed with indeterminate pulmonary nodules or Lung Cancer from the screening phases. Exclusion Criteria: * Subjects under 40 years of age * Unable to be followed-up for at least 2-years or complete the study * Subjects that do not sign the informed consent * Current or prior history of lung cancer * History of neoplasia in the previous 5 years except non-melanoma skin cancer * Moderate-severe comorbidities that prevent completion of a diagnostic study in the event of findings suggestive of lung neoplasia (by means of the investigator's clinical judgment) or surgical intervention (\< 6 months) if not previously confirmed by cytohistology. * Vulnerable subjects: severe psychiatric comorbidity, adults under guardianship or deprived of liberty * Pregnant women